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Abstract
Purpose Although vaginal dilator use after combined pelvic
radiation therapy and brachytherapy (RT/BT) is recommend-
ed to prevent vaginal shortening and stenosis, women fail to
use them and experience sexual problems. A nurse-led sexual
rehabilitation intervention targeting sexual recovery and vag-
inal dilatation was developed. Its feasibility was investigated
during a prospective, longitudinal, observational pilot study.
Methods Four oncology nurses were specifically trained to
conduct the intervention. Gynecologic cancer patients treated
with RT/BTwere assessed using (i) questionnaires on frequency
of dilator use (monthly), sexual functioning, and sexual distress
(at baseline and 1, 6, and 12 months) and psychological and
relational distress (at 1, 6, and 12 months); (ii) semi-structured
interviews (between 6 and 12 months); and (iii) consultation
recordings (a random selection of 21 % of all consults).
Results Twentyparticipantswere26–71years old (mean=40).
Eight participants discontinued participation after 3 to
9 months. At 6 months after RT, 14 out of 16 (88 %), and at
12 months 9 out of 12 (75 %), participants dilated regularly,
either by having sexual intercourse or by using dilators.
Sexual functioning improved between 1 and 6 months after
RT, with further improvement at 12 months. Most participants
reported that the intervention was helpful and the nurses re-
ported having sufficient expertise and counseling skills.
Conclusions According to the pilot results, the intervention
was feasible and promising for sexual rehabilitation and reg-
ular dilator use after RT. Its (cost-)effectiveness will be inves-
tigated in a randomized controlled trial.
Keywords Gynecological cancer . Pelvic radiation therapy
and brachytherapy . Sexual rehabilitation . Dilator use
compliance . Nurse-led intervention
Introduction
About 35% of gynecologic cancer survivors (GCSs) are treat-
ed with primary or postsurgical pelvic radiotherapy (RT) [1].
Patients with more advanced cervical cancer (CC) and vaginal
cancer are treated with primary chemoradiotherapy, consisting
of pelvic external beam radiation and intrauterine brachyther-
apy (EBRT/BT), with concurrent cisplatin-based chemothera-
py, most often 5–6 weekly infusions of cisplatin 40 mg/m2 [2,
3]. Brachytherapy is started in the final week(s) of EBRT to
ensure an overall treatment duration of less than 50 days.
Image-guided adaptive BT based on volumetric imaging
(CT/MRI) has improved efficacy and decreased late morbidity
after treatment [4]. Nevertheless, treatment with RT has been
associated with sexual dysfunction among both GCS and their
partners [5–9]. The negative effect of EBRT/BT on sexual
functioning is caused by shortening and tightening of the va-
gina, reduced flexibility, and decreased lubrication, induced
by fibrosis and stenosis and mucosal atrophy [10–12].
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Regular vaginal dilator use after EBRT/BT has been asso-
ciated with reduced vaginal shortening and/or tightening, al-
thoughmore empirical evidence is needed regarding the effect
in reducing sexual problems [13–17]. Regular dilator use has
become an essential component of the sexual rehabilitation of
GCS worldwide [16, 18, 19]. In spite of this, most patients
(75 %) reported being unable to follow dilator use instruc-
tions, for example due to being anxious about pain or blood
loss, negative emotions regarding dilator use or EBRT/BT, or
a lack of support or routine [15, 20–22]. Support during reha-
bilitation is therefore needed to help GCS experience fewer
problems during dilator use and when resuming sexual
activity.
An Australian study found that a specific information
booklet [23] somewhat increased dilator use 3 and 6 months
after treatment compared to Bcare as usual^ (CAU) [24, 25].
Two small Canadian trials compared the effect of two addi-
tional psychologist-led group sessions at 1 and 2 months after
treatment to CAU [26, 27]. The intervention group used the
dilators more frequently (65 %) than the CAU group (38 %) at
6 weeks, but no significant difference was found after
6 months (31 versus 19 %) [26, 27]. The abovementioned
interventions, however, found no difference with regard to
sexual functioning. The efficacy of sexual rehabilitation inter-
ventions may increase by addressing other psychosocial and
somatic aspects of sexual functioning possibly affected by
cancer treatment, addressing both partners’ knowledge and
fears, promoting couples’ mutual coping to improve sexual
health, and including specific sexual therapy techniques [10,
28]. Furthermore, it is worthwhile providing follow-up ses-
sions during 1 year after RT to ensure continued support dur-
ing the recommended 12-month period of dilator use and to
investigate whether oncology nurses, who are closely in-
volved with patients during follow-up, would be able to con-
duct such an intervention after a special training in sexology.
There are no published effective interventions to support
GCS with sexual recovery and long-term regular dilator use.
Therefore, this prospective, longitudinal, observational pilot
study tested a sexual rehabilitation intervention combined
with a specific patient information booklet for its clinical fea-
sibility. The intervention was directed at increasing knowl-
edge and offering coping strategies to both patients and their
partners with respect to sexual issues after treatment and ben-
efits of dilator use and increasing long-term compliance with
dilator use.
Materials and methods
Participant selection
In line with experts’ recommendations with regard to which
patients should be offered support after treatment [18], eligible
patients were 18 to 70 years old and had to be treated with
primary or postsurgical EBRT/BT for gynecologic cancer. In
practice, primary EBRT/BT is mainly given to patients with
cervical cancer (primary treatment for International Federation
of Obstetrics and Gynecology (FIGO) stages IB2–IIIB) or
vaginal cancer (stages I–III) and postsurgical EBRT/BT main-
ly for cervical cancer (FIGO stage IB1) or endometrial cancer
(stage II or III). Women older than 70 were only invited to
participate if they were sexually active and wished to resume
sexual activity after treatment. Patients with insufficient
knowledge of the Dutch language or major psychological
problems were excluded and offered counseling by a senior
clinical psychologist specialized in sexual rehabilitation. The
Leiden University Medical Center Medical Ethics Committee
approved the protocol (NL44759.058.13). All participating
women provided written informed consent.
The intervention
A patient information booklet entitled BSexuality after pelvic
radiation for gynecologic cancer: information for women and
their partners^ was developed. The booklet was developed in
collaboration with a multidisciplinary team of sexologists, ra-
diation oncologists, gynecologic oncologists, and oncology
nurses. The booklet was subsequently pilot tested by GCS,
healthy lower-educated women, and patient advocates from
the Dutch gynecologic cancer patient support group
BStichting Olijf^. The initial draft of the booklet was partly
based on an Australian brochure with permission [23].
A team of clinical psychologist-sexologists developed the
intervention based on previous study and intervention results
[18, 20, 29, 30]. Two senior psychologist-sexologists devel-
oped and provided the nurses’ training program and monthly
2-h group supervision. The intervention comprised four face-
to-face counseling sessions at 1, 2, 3, and 6 months after
completion of EBRT/BT. An evaluation and closing session
was scheduled at 12 months after EBRT/BT. The sessions
were planned in line with their radiation oncologist follow-
up visits, except for the session at 2 months. Although not
obligatory, the partners of participants in a relationship were
invited to join the sessions. The sessions were adapted to the
relationship status of participants and the possible partners’
presence. During the first session, participants were informed
about the intervention, their diagnosis, therapy and possible
treatment consequences, and the importance of long-term reg-
ular dilator use. Furthermore, participants were recommended
to start vaginal dilator use and provided with instructions [18].
Avaginal dilator set, lubricants, and information booklet were
provided for free by the participating hospitals.
During the second session, possible barriers to new behav-
iors such as dilator use, lubricant use, and fear of penetration
during dilator use or while resuming sexual activity were
discussed. Nurses provided tailored advice depending on the
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participants’ situation and reported issues. During the third
and fourth sessions, participants’ experiences with sexual re-
habilitation and dilator use were discussed, and again, tailored
advice was given. Couples’ mutual coping and support pro-
cesses were promoted, and specific interventions to address
sexual, body image and relationship concerns were included.
A follow-up session at 12 months was scheduled to evaluate
the course of the sexual rehabilitation in the past year and
provide future advice. Furthermore, an extra session could
be scheduled between 6 and 12 months after treatment.
The nurses’ training
Four oncology specialist nurses conducted the intervention af-
ter receiving 50 hours of skill training. Two senior clinical psy-
chologist-sexologists, with expertise in the conceptualization,
methods, and skills, developed and provided the nurses’ train-
ing program. The training was provided during 6 days, spread
over a period of 3 months, and covered the basic principles of
sexology, motivational interviewing [31–33], cognitive behav-
ioral interventions [30, 34, 35], and the treatment protocol itself.
The training was delivered using a combination of lecture-style
presentation (30 %), role-play and group discussions (35 %),
and small-group practice sessions (35 %). Also, guest speakers
(a radiation oncologist and gynecologic oncologist) provided
education on surgical and radiation treatments, with emphasis
on the treatment-related toxicities and management thereof.
The nurses received copies of the treatment manual, patient
information booklet, and a handbook with the presentations’
handouts. During the study period (around 2 years), the nurses
receivedmonthly 2-hour group supervision from one of the two
clinical psychologist-sexologists.
Measures
Information was collected frommedical records with regard to
age, type of cancer, FIGO stage, and hormone replacement
therapy (HRT).
Primary outcome measures
Sexual functioning was measured with the 19-item Female
Sexual Function Index (FSFI) total score concerning the sub-
scale sexual desire, arousal, lubrication, orgasm, satisfaction,
and genital pain. It was conducted at inclusion to obtain infor-
mation retrospectively about the participants’ situation prior to
any diagnosis-related complaints and at 1, 6, and 12 months
after RT. Answers are measured with 5- or 6-point Likert
scales, and a higher total score (ranging from 2 to 36) indicates
better sexual function. The FSFI has been validated among
female cancer survivors and showed a good reliability
(Cronbach’s α = 0.94 and 0.82 in the current pilot sample)
[36].
Secondary outcome measures
Frequency of vaginal dilatation was assessed monthly using
four questions about dilator use frequency, duration, sexual
intercourse frequency, and alternative dilator use. Sexually
related personal distress was measured with the Female
Sexual Distress Scale (FSDS). The FSDS was completed also
retrospectively at inclusion and at 1, 6, and 12 months after
RT. A higher total score (ranging from 0 to 48) indicates more
sexually related personal distress [37]. The subscales Anxiety
and Depression of the Hospital Anxiety and Depression Scale
(HADS) were used to measure anxiety and depression [38].
The subscale Marital (Mal)adjustment of the Maudsley
Marital Questionnaire (MMQ) was used to measure relation-
ship dissatisfaction [39]. Higher scores indicate more symp-
tom burden on the three questionnaires. The HADS and
MMQ were completed at 1, 6, and 12 months after RT.
Patients’ and nurses’ exit interviews
Structured exit interviews were conducted among participants
after their last nurse-led consultation at 6 months and before
the evaluation session with their nurse at 12 months. They
were asked about their experiences with vaginal dilator use,
sexual activity, the supportiveness and acceptability of all
components of the sexual rehabilitation intervention (includ-
ing the information booklet), and reasons for discontinuing
their participation. The interviews additionally served as a
concluding consultation with the researchers about the burden
and logistics of the assessments and appointments. Two re-
searchers (RB and MK) that were not involved in the inter-
vention conducted the interviews. Subsequently, they were
verbally transcribed, and the researchers summarized partici-
pants’ most important evaluations through negotiated
consensus.
Exit interviewswere also conducted with the nurses regard-
ing the feasibility of the intervention. Furthermore, all nurses’
consultations were digitally recorded. Two independent re-
search assistants assessed the nurses’ adherence with the treat-
ment protocol and general competency in a sample of 18 out
of 85 consults (21 %).
Statistical methods
Descriptive statistics were used to evaluate participant charac-
teristics and to assess the nurses’ consultations. Non-
parametric tests were conducted to analyze the outcome mea-
surements among this small, not normally distributed, pilot
sample. Therefore, two-sided, Friedman’s ANOVA’s and post
hoc Wilcoxon signed rank tests for paired samples were used
to investigate differences between baseline and the subsequent
questionnaires during the study period. Effect sizes for post
hoc comparisons were reported as r and classified as small
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(r = 0.1–0.03), intermediate (r = 0.3–0.5), or strong (r ≥ 0.5)
[40]. Due to the hypothesis-generating nature of the pilot
study, no corrections for multiple testing were applied. A sig-
nificance level of 5 % was used in all analyses. Analyses were
conducted using IBM SPSS version 20 (Armonk, NY, USA).
Results
Participant characteristics
Of the 74 patients that received EBRT/BT at 1 of the hospitals
during the study period, 34 patients (46 %) were eligible for
the study, of whom 31 (91 %) were invited and 20 (62 %)
agreed to participate (see Fig. 1). Participants were between 26
and 71 years of age (mean (M) = 40 ± 11 years) and either
treated for cervical (n = 18, 90%), vaginal cancer (n = 1, 5 %),
or endometrial cancer (n = 1, 5 %). Fourteen participants were
in a partner relationship at the time of inclusion for an average
of 15 years (±13). In total, 16 participants used vaginal estriol
3 times weekly during 6 weeks (2 to 8 weeks after RT) and 14
participants used HRT (see Table 1).
Four participants stopped participation before the 6-month
assessment and another four in the subsequent 6 months (see
Fig. 1 and Table 2). Participants had on average 4.5 sessions
with their oncology nurse, lasting between 8 and 73 min per
session (M = 29 ± 6 min).
Primary outcome measures
Participants’ sexual functioning significantly changed over
time (χ2 (3) = 18.00, p < 0.001). Compared to their situation
before diagnosis, participants reported lower levels of sexual
functioning at 1 month (p < 0.001, r = −0.60), as well as at
6 months after RT (p < 0.001, r = −0.59). However, after
treatment with RT, participants’ sexual functioning signifi-
cantly increased over time. Compared to 1 month after RT,
participants’ reported higher levels of sexual functioning at
6 months (p = 0.011, r = −0.42) and at 12 months after RT
(p = 0.012, r = −0.44) and continued to improve between 6
and 12 months after RT (p = 0.015, r = −0.46). Their sexual
functioning at 12months was comparable to prior to diagnosis
(p = 0.346, r = −0.17) (see Fig. 2 and Online Resource 1).
Secondary outcome measures
At 6 months, 14 out of 16 participants (88 %) reported using
dilators at least twice a week. At 12 months, 9 out of 12
remaining participants (75 %) dilated at least twice a week
and 11 at least once a week (92 %) (see Fig. 3). Participants
performed dilation either by resuming sexual intercourse or
using vaginal dilators, while 13 (65 %) reported having used
other types of dilators at least once, namely, vibrators (n = 6,
30 %), Vaseline tampons (n = 4, 20 %), or fingers (n = 7,
35 %). At 6 months, partnered participants (n = 11) gradually
Eligible: N = 34 (46% of treated)
Not eligible: N = 40 (54%)
Older than 70 years: N = 25
Language barrier: N = 4
Living abroad or in nursing home: N = 4
Treatment local hospital: N = 4
Metastasis: N = 2
Psychiatric treatment: N = 1
Paents treated with EBRT/BT 
between 1-10-2013 and 1-02-2015:
N = 74
Invited: N = 31 (91% of eligible)
Refused to parcipate: N = 11 (35%)
Psychological burden: N = 6
No interest: N = 3
Other unstated reasons: N = 2
Parcipants: N = 20 (65% of invited)
EMC: N = 12 (60%)
LUMC: N = 8 (40%)
With partner: N = 15 (75%) 
Not invited due to logiscal errors: 
N = 3 (9%) 
Drop-out: N = 4 (20%)
Metastasis: N = 1
Necrozing infecon: N = 1
Vaginal dehiscence aer RHL: N = 1
No wish to retain sexual acvity: N = 1
6 months aer treatment
Parcipants: N = 16 (80%)
1 month aer treatment
Parcipants: N = 20 (100%)
12 months aer treatment
Parcipants: N = 12 (60%)
Drop-out: N = 4 (20%)
Recurrence: N = 2
Psychiatric treatment: N = 1
Reasons unknown: N = 1
Fig. 1 Flowchart of the participant selection. EMC Erasmus MC Cancer Institute, LUMC Leiden University Medical Center
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replaced (n = 2, 18 %) or supplemented (n = 6, 55 %) vaginal
dilator use by having sexual intercourse (see also Online
Resource 2).
Participants’ sexual distress was not significantly different
over time (χ2 (3) = 3.67, p = 0.299). Post hoc analyses
showed, however, that compared to their pre-diagnosis situa-
tion, participants reported higher levels of sexual distress at
1 month (r = −0.41, p = 0.009) and 6 months after treatment
with RT (r = −0.42, p = 0.012) and a trend for higher levels at
12 months after RT (r = −0.33, p = 0.066). Also, after treat-
ment with RT, participants’ levels of sexual distress did not
significantly decrease over time during the intervention.
Furthermore, after treatment with RT, participants’ levels of
depression (χ2 (2) = 3.50, p = 0.174), anxiety (χ2 (2) = 0.70,
p = 0.704), and relationship dissatisfaction (χ2 (2) = 3.94,
p = 0.140) did not significantly decrease over time during
the intervention. However, post hoc analyses showed that
compared to 1-month posttreatment, there were trends for
the levels of depression (r = −0.34, p = 0.061) and relationship
dissatisfaction (r = −0.33, p = 0.091) to be lower at 12 months
after RT (see Table 3 and Online Resource 1).
Patients’ and nurses’ concluding remarks
The exit interviews were conducted with 16 participants
and lasted 38 min on average. They reported that the
intervention had been helpful for dilator use and resuming
sexual activity (n = 15, 94 %). About two thirds men-
tioned having been bothered by fear of pain or bleeding
at first dilator use or sexual activity. However, they also
reported that their nurses’ support provided reassurance
and motivated them to start, which they might not other-
wise have done. Furthermore, most women (n = 12, 75 %)
read the information booklet once or twice and studied the
sexual position images more often. Furthermore, accord-
ing to the participants, having one specific nurse available
for extra consultation was important in order to talk com-
fortably about their personal situation and sexual func-
tioning. Some reported that their partners’ presence was
not needed, but others considered it important to create
mutual understanding.
The nurses reported feeling sufficiently skilled to con-
duct the intervention and to support participants. From the
Table 1 Cancer treatment and
demographic participant
characteristics
Treatment-related Demographic
Participant Cancer type
and FIGO
stage
Primary
treatment
Secondary
treatment
HRT Age
(years)
Relationship
duration
(years)
P1 CC IIB EBRT/BT – Yes 42 21
P2 CC IIB EBRT/BT – Yes 32 1
P3 EC IB RHL EBRT/BT No, declined 40 –
P4 CC IIB EBRT/BT AH Yes 32 0
P5 CC IB1 EBRT/BT – Yes 43 –
P6 CC IB2 EBRT/BT – Yes 31 –
P7 CC IIB RHL EBRT/BT Yes 35 14
P8 CC IIB EBRT/BT – Yes 32 –
P9 CC IIB EBRT/BT – No, postmenopausal 57 37
P10 CC IIA EBRT/BT – Yes 26 7
P11 CC IIB EBRT/BT AH No, postmenopausal 51 20
P12 CC IB1 EBRT/BT – No, postmenopausal 71 45
P13 CC IB2 EBRT/BT – Yes 43 –
P14 VC IIB EBRT/BT – Yes 41 –
P15 CC IB2 EBRT/BT – Yes 39 7
P16 CC IIB EBRT/BT – Yes 31 4
P17 CC IB1 EBRT/BT LND/OD No, adequate
function of
displaced ovary
26 3
P18 CC IB1 EBRT/BT LND/OD Yes 28 11
P19 CC IIB EBRT/BT – No, declined 46 14
P20 CC IIB EBRT/BT AH No, postmenopausal 50 23
FIGO International Federation of Gynecology and Obstetrics, CC cervical cancer, EC endometrial cancer, VC
vaginal cancer, RHL radical hysterectomy with pelvic lymphadenectomy, LND lymph node dissection, OD
ovarian displacement, AH abdominal hysterectomy, HRT hormone replacement therapy
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consultation recordings, it was apparent that all nurses
adhered to the treatment protocol, with flexibility with
regard to the specific patient situation. Each nurse dem-
onstrated sufficient competence to conduct the specific
interventions.
Discussion
A nurse-led sexual rehabilitation intervention to help GCSs,
treated with EBRT/BT, to initiate vaginal dilator use and ad-
dress sexual issues, anxieties, and coping problems in the
Table 2 Intervention-related
participant characteristics Intervention-related Drop-out related
Participant No. of sessions (by
telephone)
Total
duration
(min)
No. of months
after RT
Reason
P1 5 112 – –
P2 3 150 5 Necrotizing infection
P3 2 42 4 No interest sexual activity
P4 6 304 – –
P5 5 (1) 107 – –
P6 5 103 – –
P7 6 218 – –
P8 5 167 – –
P9 5 61 – –
P10 6 (2) 135 – –
P11 4 69 5 Vaginal dehiscence after surgery for
residual disease
P12 4 109 – –
P13 6 118 – –
P14 6 160 – –
P15 4 71 9 Recurrence
P16 3 42 6 Unknown
P17 4 224 8 Psychiatric treatment
P18 5 239 – –
P19 4 195 8 Recurrence
P20 2 101 3 Metastasis (palliative care)
25.22
9.71
17.69
23.38
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* r = -.44Fig. 2 Sexual functioning
assessed retrospectively about
pre-diagnosis and during the
intervention at 1, 6, and
12 months after treatment
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recovery phase was developed, and its feasibility was pilot
tested. During the intervention, participants’ sexual function-
ing improved and most participants dilated regularly either by
gradually resuming sexual intercourse or by using vaginal
dilators or other types of dilation (e.g., vibrator or fingers).
Sexual distress, however, continued to be elevated during
the 12 months of the intervention. However, as this was a
non-randomized feasibility study, a randomized efficacy study
should investigate whether the improvements were due to the
intervention itself. Most participants reported that the inter-
vention was helpful and the nurses reported having sufficient
expertise.
For the first time, the long-term sexual functioning of GCS
was studied extensively and was shown to improve and return
to participants’ reported pre-diagnosis levels, during a 12-
month sexual rehabilitation intervention [27]. Therefore, it is
possible that more follow-up sessions during the first 6 to
12 months after RT and the invitation to the patients’ partners
to join the sessions lead to better and more sustained sexual
recovery among GCS than short individual or peer-group in-
terventions [28].
In contrast to previous studies, a large proportion of this
study’s participants continued regular long-term dilator use
and gradually replaced it with sexual intercourse as well
[27]. Jeffries et al. (2006) showed that at 6 months, 4 months
after the intervention, only 31 % of the participants dilated at
least twice a week [26]. This may be in line with the sugges-
tion that more follow-up sessions may motivate GCS with
dilator use and our compliance rate of 88 % is promising.
Furthermore, the trend for participants’ decreased levels of
depression and relationship dissatisfaction at 12 months ap-
peared to indicate better functioning compared to previous
GCS cohorts who received no specific support after treatment
[7, 41]. However, participants reported continued sexual dis-
tress levels that were comparable with the sexual distress
levels reported among a cohort of 72 cervical cancer survivors
evaluated 64 months (±33) after EBRT/BT [41]. Our study’s
participants were evaluated early in the recovery phase, and
0
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7
1 2 3 4 5 6 7 8 9 10 11 12
)02
=
n(
kee
wrep
ycneuqerf
noitalid
egarevA
Time (months)
Total
Intercourse
Recommended
Fig. 3 Average dilation
frequency per week (n = 20)
Table 3 Outcome measurements completed retrospectively about pre-diagnosis and during the intervention at 1, 6, and 12 months after treatment
0-month mean
(±SD)b
1-month mean
(±SD)
6-month mean
(±SD)
12-month mean
(±SD)
χ2 p
value
Post hoc
analyses
a b c d
n = 20 n = 20 n = 16 n = 12
Measurea
Sexual functioning 25.22 (6.31) 9.71 (8.44) 17.69 (8.13) 23.38 (8.58) 18.00* <0.001 b < c < d = a
Sexual distress 10.25 (11.06) 18.25 (13.81) 17.94 (13.84) 18.91 (12.00) 3.67 0.299 b = c = d > a
Relationship
dissatisfaction
– 20.65 (30.97) 12.00 (8.57) 7.70 (5.87) 3.94** 0.140
Anxiety – 5.80 (4.20) 5.88 (3.81) 4.91 (3.48) 0.70 0.704
Depression – 5.30 (3.84) 3.94 (3.45) 2.73 (3.72) 3.50** 0.174
*Significant difference with p < 0.05; **post hoc analyses showed a trend for b = c > d with p < 0.10
a Sexual functioning Female Sexual Functioning Index, sexual distress Female Sexual Distress Scale, anxiety and depression Hospital Anxiety and
Depression Scale Subscales Anxiety and Depression, relationship dissatisfactionMaudsley Marital Questionnaire
b SD standard deviation
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therefore, it should be noted that sexual distress among GCS
may further recover between 12 and 24 months [9]. How
much improvement can be achieved after a sexual rehabilita-
tion intervention compared with care as usual in the long term
is unknown.
Although the results obtained in this intervention study
are promising, several comments can be made for future
reference. Given the uncontrolled nature of this pilot
study, it can be argued that the improvement in sexual
functioning to pre-diagnosis levels was due merely to
the passage of time and that the extra contact with pro-
fessionals may also improve sexual problems of GCS [9].
In addition, despite the clinical evidence that vaginal di-
latation is associated with reduced vaginal complaints and
better sexual rehabilitation, firm evidence for its effective-
ness is still lacking. Furthermore, a possible selection bias
may have occurred since 55 % (6 out of 11) of the pa-
tients who declined felt that participation would be a psy-
chological burden. Therefore, the current participants may
have experienced less distress or better coping mecha-
nisms. Lastly, this study’s dropout rate of 40 % was
higher than the 20 % that was expected based on previous
intervention studies [26, 27]. However, dropout was only
due to disease-related issues. Also, the recruitment of 10
to 15 participants is considered adequate for the purpose
of a pilot study [42].
Based on our pilot findings, this study’s intervention
has proven to be feasible and promising and may im-
prove support for GCS during sexual recovery and vag-
inal dilatation after EBRT/BT. We are now one step clos-
er to improving sexual health-related care for EBRT/BT
survivors. To follow up on participants’ improvement
during the current nurse-led sexual rehabilitation inter-
vention, long-term efficacy should be investigated in a
larger controlled study. Therefore, to evaluate its
(cost-)effectiveness, a multicenter, randomized trial with
a control group receiving standard care will be initiated.
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